FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213309979> ?p ?o ?g. }

• W4213309979 endingPage "TPS201" @default.
• W4213309979 startingPage "TPS201" @default.
• W4213309979 abstract "TPS201 Background: Androgen receptor signaling inhibitors (ARSI), such as enzalutamide (Enza), and abiraterone (Abi), are standard therapies for metastatic hormone-sensitive and metastatic castration-resistant prostate cancer (mHSPC, mCRPC). Patients who respond to the initial ARSI are frequently prescribed a second ARSI upon progression. However, a suboptimal response to first line ARSI, including the ̃ 20% treated with an ARSI for mHSPC who progress within 12 months of treatment initiation, may enrich for cancers harboring AR-independent mechanisms of resistance including treatment-emergent neuroendocrine prostate cancer (t-NEPC). Recently, BETi have been shown pre-clinically to block the neuroendocrine prostate cancer lineage plasticity program through modulating E2F1, a transcription factor involved in stemness and cell differentiation. Prior results from a mCRPC Ph. 1b/2a trial of ZEN-3694+ Enza support this notion, as lower AR transcriptional activity in baseline tumor biopsies was associated with longer radiographic progression-free survival (rPFS). Additionally, mCRPC patients who were primary refractory to first-line abiraterone had prolonged rPFS with ZEN-3694 + Enza, suggesting that the patients with primary resistance may benefit from the combination. To test this hypothesis, a Ph. 2b randomized trial has been initiated, enriching for mCRPC with suboptimal response to first-line ARSI. Methods: This is a multi-national, open-label, randomized, two cohort, Ph. 2b study of ZEN-3694 + Enza vs. Enza in mCRPC patients who have progressed on Abi (NCT04986423). Cohort A (N = 150): Patients with poor response to Abi defined either as progression in < 12 months or failure to achieve PSA nadir of 0.2 ng/mL while taking Abi in HSPC setting, or progression in < 6 months and/or failure to achieve a PSA50 response while taking Abi in the CRPC setting. Cohort B (N = 50): Patients who responded to Abi, defined as > 12 months duration without progression while on Abi in the HSPC setting and achieving a nadir PSA < 0.2 ng/mL, or > 6 months duration without progression while on Abi in the CRPC setting and confirmed PSA50 response. The primary endpoint is radiographic progression-free survival (rPFS) by blinded independent central review (BICR) in Cohort A evaluated by PCWG3. Key secondary endpoints include rPFS by BICR for Cohorts A + B, PFS by investigator assessment, overall survival, PSA50 response rate, objective response rate by RECIST 1.1, and patient-reported health status and quality of life, evaluated in Cohorts A, and Cohorts A + B together. The trial, conducted in collaboration with Newsoara is expected to enroll 200 participants, and the first patient was dosed in October 2021. Astellas is providing the enzalutamide for this study. Clinical trial information: NCT04986423." @default.
• W4213309979 created "2022-02-24" @default.
• W4213309979 creator A5000300496 @default.
• W4213309979 creator A5008411106 @default.
• W4213309979 creator A5014339741 @default.
• W4213309979 creator A5015130241 @default.
• W4213309979 creator A5017292379 @default.
• W4213309979 creator A5018902276 @default.
• W4213309979 creator A5028358539 @default.
• W4213309979 creator A5028538472 @default.
• W4213309979 creator A5043883865 @default.
• W4213309979 creator A5052694721 @default.
• W4213309979 creator A5061552915 @default.
• W4213309979 creator A5065154340 @default.
• W4213309979 creator A5081123075 @default.
• W4213309979 creator A5082994382 @default.
• W4213309979 date "2022-02-20" @default.
• W4213309979 modified "2023-10-01" @default.
• W4213309979 title "A randomized mCRPC phase 2b study of the BET bromodomain inhibitor (BETi) zen-3694 and enzalutamide vesus enzalutamide." @default.
• W4213309979 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.tps201" @default.
• W4213309979 hasPublicationYear "2022" @default.
• W4213309979 type Work @default.
• W4213309979 citedByCount "0" @default.
• W4213309979 crossrefType "journal-article" @default.
• W4213309979 hasAuthorship W4213309979A5000300496 @default.
• W4213309979 hasAuthorship W4213309979A5008411106 @default.
• W4213309979 hasAuthorship W4213309979A5014339741 @default.
• W4213309979 hasAuthorship W4213309979A5015130241 @default.
• W4213309979 hasAuthorship W4213309979A5017292379 @default.
• W4213309979 hasAuthorship W4213309979A5018902276 @default.
• W4213309979 hasAuthorship W4213309979A5028358539 @default.
• W4213309979 hasAuthorship W4213309979A5028538472 @default.
• W4213309979 hasAuthorship W4213309979A5043883865 @default.
• W4213309979 hasAuthorship W4213309979A5052694721 @default.
• W4213309979 hasAuthorship W4213309979A5061552915 @default.
• W4213309979 hasAuthorship W4213309979A5065154340 @default.
• W4213309979 hasAuthorship W4213309979A5081123075 @default.
• W4213309979 hasAuthorship W4213309979A5082994382 @default.
• W4213309979 hasConcept C121608353 @default.
• W4213309979 hasConcept C126322002 @default.
• W4213309979 hasConcept C143998085 @default.
• W4213309979 hasConcept C2775832370 @default.
• W4213309979 hasConcept C2776551883 @default.
• W4213309979 hasConcept C2777899217 @default.
• W4213309979 hasConcept C2780192828 @default.
• W4213309979 hasConcept C61367390 @default.
• W4213309979 hasConcept C71924100 @default.
• W4213309979 hasConcept C72563966 @default.
• W4213309979 hasConceptScore W4213309979C121608353 @default.
• W4213309979 hasConceptScore W4213309979C126322002 @default.
• W4213309979 hasConceptScore W4213309979C143998085 @default.
• W4213309979 hasConceptScore W4213309979C2775832370 @default.
• W4213309979 hasConceptScore W4213309979C2776551883 @default.
• W4213309979 hasConceptScore W4213309979C2777899217 @default.
• W4213309979 hasConceptScore W4213309979C2780192828 @default.
• W4213309979 hasConceptScore W4213309979C61367390 @default.
• W4213309979 hasConceptScore W4213309979C71924100 @default.
• W4213309979 hasConceptScore W4213309979C72563966 @default.
• W4213309979 hasIssue "6_suppl" @default.
• W4213309979 hasLocation W42133099791 @default.
• W4213309979 hasOpenAccess W4213309979 @default.
• W4213309979 hasPrimaryLocation W42133099791 @default.
• W4213309979 hasRelatedWork W2013982033 @default.
• W4213309979 hasRelatedWork W2770702948 @default.
• W4213309979 hasRelatedWork W2776594178 @default.
• W4213309979 hasRelatedWork W2783882412 @default.
• W4213309979 hasRelatedWork W2948798859 @default.
• W4213309979 hasRelatedWork W3023947295 @default.
• W4213309979 hasRelatedWork W3156855168 @default.
• W4213309979 hasRelatedWork W3202359850 @default.
• W4213309979 hasRelatedWork W4205706045 @default.
• W4213309979 hasRelatedWork W4229076799 @default.
• W4213309979 hasVolume "40" @default.
• W4213309979 isParatext "false" @default.
• W4213309979 isRetracted "false" @default.
• W4213309979 workType "article" @default.